Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.

Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.